talkbio – Page 2

Tyra Biosciences Strengthens Leadership with Appointment of Bhavesh Ashar as COO and Heather Faulds as CRO

2 days ago talkbio0Tagged Bhavesh Ashar, biology (field), Chief Operating Officer, Chief Regulatory Officer, Drug Development, Fibroblast Growth Factor Receptors, Heather Faulds, Neoplasms, Precision Medicine, regulatory strategy, Tyra Biosciences

Tyra Biosciences; Bhavesh Ashar; Heather Faulds; Chief Operating Officer; Chief Regulatory Officer; oncology; precision medicine; FGFR biology; drug development; regulatory strategy

Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Global Markets

2 days ago talkbio0Tagged Amgen settlement, Biocon Biologics, Biosimilars, biosimilars approval, bone health, Commission, denosumab, entry - ActRelationshipCheckpoint, Europe market, European (ethnic group), Evfraxy, Neoplasms, Vevzuo

Biocon Biologics; Denosumab biosimilars; Vevzuo; Evfraxy; Europe market entry; Amgen settlement; biosimilars approval; European Commission; bone health; oncology

MediView Achieves First CE Mark, Bringing Augmented Reality to European Healthcare

2 days ago talkbio0Tagged augmented, Augmented Reality, CE Mark, clinical visualization, European (ethnic group), GE HealthCare, Health care facility, Interventional radiology, MediView, MediView XR, MediView XR90, reality

MediView; CE Mark; augmented reality; European healthcare; mixed reality; clinical visualization; MediView XR; MediView XR90; GE Healthcare; interventional radiology

Kane Biotech Announces Third Quarter 2025 Financial Results

2 days ago talkbio0Tagged Clearance, distributor network, financial results, gross profit, Kane Biotech, net loss, Revenue, revyve, third quarter 2025, United States, United States Food and Drug Administration, wound care

Kane Biotech; third quarter 2025; financial results; revenue; gross profit; net loss; revyve; wound care; FDA 510(k) clearance; U.S. distributor network

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at CTAD Conference

2 days ago talkbio0Tagged access program, Alzheimer 's disease, Clinical Trials, Cognition Therapeutics, CTAD, Lewy bodies, Neurodegenerative Disorders, Phase 3 clinical trial, Presenile dementia, sigma-2 receptor, Zervimesine

Cognition Therapeutics; Zervimesine; CT1812; Phase 3 clinical trial; Alzheimer’s disease; Clinical Trials on Alzheimer’s Disease (CTAD); neurodegenerative diseases; sigma-2 receptor; dementia with Lewy bodies; expanded access program

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

2 days ago talkbio0Tagged annual, Antibody-Drug Conjugates, Asymmetric Septal Hypertrophy, CD64-targeting ADC, Leukemia, Myelocytic, Acute, Leukemia, Myelomonocytic, Chronic, meeting, Monocytic leukemia, OncoPrecision, Resistance (Psychotherapeutic)

OncoPrecision; ONC001; CD64-targeting ADC; monocytic leukemia; acute myeloid leukemia; ASH Annual Meeting; antibody-drug conjugate; CMML; therapy resistance

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

2 days ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, ARPA-H grant, CAR-T, Clinical Trials, Gene Writing, genome engineering, in vivo, Lipid Nanoparticles, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Gene Writing; in vivo CAR-T; ARPA-H grant; Regeneron partnership; TSRA-196; alpha-1 antitrypsin deficiency; Lipid Nanoparticles; in vivo genome engineering; clinical trials

FDA’s Vinay Prasad Links 10 Child Deaths to COVID-19 Vaccines, Calls for Stricter Review Guidelines

2 days ago talkbio0Tagged Biological Factors, COVID19 (disease), Death of child, Evaluation, Myocarditis, United States Food and Drug Administration, vaccine guidelines, vaccine regulation, Vaccine Safety, Vaccines, VAERS, Vinay Prasad

FDA; Vinay Prasad; COVID-19 vaccines; child deaths; myocarditis; vaccine safety; vaccine regulation; biologics evaluation; VAERS; stricter vaccine guidelines

Generate:Biomedicines Launches Global Phase 3 Trials for AI-Engineered Anti-TSLP Antibody GB-0895 in Severe Asthma

2 days ago talkbio0Tagged AI-engineered antibody, Asthma, Biomedicines, Clinical Trials, GB-0895, Generate, Phase 3, Programmable Biology, Severe (severity modifier), SOLAIRIA-1, SOLAIRIA-2, thymic stromal lymphopoietin, TSLP gene

Generate:Biomedicines; GB-0895; Phase 3 clinical trials; TSLP; thymic stromal lymphopoietin; severe asthma; AI-engineered antibody; programmable biology; SOLAIRIA-1; SOLAIRIA-2

AcuCort Appoints Nomination Committee for 2026 Annual General Meeting

2 days ago talkbio0Tagged AcuCort, annual, General Meeting, Jonmark, nomination committee, representatives, shareholder

AcuCort; nomination committee; 2026 annual general meeting; shareholder representatives; Jonas Jonmark; Zoya Invest